首页> 中文期刊>环球中医药 >中药干预心肌线粒体内膜能量代谢障碍的疗效:基于动物模型的系统评价

中药干预心肌线粒体内膜能量代谢障碍的疗效:基于动物模型的系统评价

     

摘要

目的:系统评价中药对动物心肌线粒体内膜能量代谢障碍的干预疗效。方法计算机检索PubMed(1966~2015.7)、Embase(1966~2015.7)、CBM(1978~2015.7)、CNKI(1915~2015.7)、VIP(1989~2015.7)及Wanfang(1990~2015.7)等数据库,纳入中药干预心肌线粒体内膜能量代谢障碍的动物实验,由2名研究者独立评价纳入研究的质量、提取数据并交叉核对,使用RevMan 5.2软件进行Meta分析。结果共纳入16个研究,系统评价及Meta分析结果显示:中药可提高线粒体态3呼吸速率[P<0.001,I2=0%],增加内膜C I[P<0.0001,I2=0%]、C II[P=0.006,I2=0%]、C IV [P<0.00001,I2=0%]、Cyt c[P<0.0001,I2=40%]活性。结论中药可通过干预心肌线粒体内膜能量代谢障碍发挥临床疗效,但基于此病理生理机制的中医药研究尚缺乏系统性。%Objective To assess the efficacy of Chinese herbal medicines for myocardial mitochondrial inner membrane energy metabolism disorders based on animal models. Methods We searched PubMed(1966~2015. 7),Embase(1966 ~2015. 7),CBM(1966 ~2015. 7),CNKI(1915 ~2015. 7),VIP(1989~2015. 7) and Wanfang(1989~2015. 7) databases. All researches based on animal models of treating myocardial mitochondrial inner membrane energy metabolism disorders with Chinese herbal medicines versus untreated groups were included. Data were extracted independently by two reviewers. Meta-analyses were conducted by the RevMan 5. 2 software. Results Sixteen researches were included. The Meta-analysis results showed that: Chinese herbal medicines could elevate the State 3 respiratory rate of myocardial mitochondria[P<0. 001,I2=0%], and up-regulated the activity of ETC CI [P<0. 0001,I2=0%],CII[P=0. 006,I2=0%],CIV[P<0. 00001,I2=0%] and Cyt c[P<0. 0001,I2=40%] . Conclusion Chinese herbal medicines may be clinically effective in treating myocardial mitochondrial inner membrane energy metabolism disorders,while the related researches based on this phys-iopathological mechanism are still lacking systematicness.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号